Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that PD-L1 (CPS) >= 1 status confers therapeutic sensitivity to Carboplatin, Paclitaxel, Pembrolizumab in patients with Cervical Adenocarcinoma.
The Republic of Ireland's Health Service Executive (HSE) has approved pembrolizumab in combination with paclitaxel (175 mg/m^2) and carboplatin (AUC-5) for reimbursement as a treatment option for the treatment of adult patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 with a combined positive score (CPS) >= 1.
This statement is based on a regulatory approval from the Health Service Executive:
Treatment of persistent, recurrent, or metastatic cervical cancer in adults whose tumours express PD-L1 with a CPS >= 1.